Publications

1. Ho MF, Zhang C, Cohan JS, Tuncturk M, Heider RM, Coombes BJ, Biernacka J, Moon I, Skime M, Ho AM, Ngo Q, Skillon C, Croarkin PE, Oesterle TS, Karpyak VM, Li H, Weinshilboum RM. IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study. Brain Behav Immun. 2024 Aug; 120:304-314 Epub 2024 June 08
   View PubMed
2. Gao H, Wei L, Indulkar S, Nguyen TTL, Liu D, Ho MF, Zhang C, Li H, Weinshilboum RM, Ingle JN, Wang L. Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy. Breast Cancer Res. 2024 Jul 4; 26 (1):111 Epub 2024 July 04
   View PubMed
3. Ho MF, Zhang C, Moon I, Zhu X, Coombes BJ, Biernacka J, Skime M, Oesterle TS, Karpyak VM, Schmidt K, Gliske K, Ngo Q, Skillon C, Seppala MD, Li H, Weinshilboum RM. Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder. Mol Psychiatry. 2024 Jun; 29 (6):1636-1646 Epub 2022 Oct 27
   View PubMed
4. Ho MF, Zhang C, Moon I, Tuncturk M, Coombes BJ, Biernacka J, Skime M, Oesterle TS, Karpyak VM, Li H, Weinshilboum R. Molecular mechanisms involved in alcohol craving, IRF3, and endoplasmic reticulum stress: a multi-omics study. Transl Psychiatry. 2024 Mar 26; 14 (1):165
   View PubMed
5. Ho MF, Zhang C, Moon I, Biernacka J, Coombes B, Ngo Q, Skillon C, Skime M, Oesterle T, Croarkin PE, Karpyak VM, Li H, Weinshilboum RM. Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation. Mol Metab. 2023 Nov; 77:101798 Epub 2023 Sept 07
   View PubMed
6. Karpyak VM, Coombes BJ, Geske JR, Pazdernik VM, Schneekloth T, Kolla BP, Oesterle T, Loukianova LL, Skime MK, Ho AM, Ngo Q, Skillon C, Ho MF, Weinshilboum R, Biernacka JM. Corrigendum to "Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder" [Drug Alcohol Depend. 243 (2023) 109753]. Drug Alcohol Depend. 2023 Sep 1; 250:110888 Epub 2023 July 11
   View PubMed
7. Karpyak VM, Coombes BJ, Geske JR, Pazdernik VM, Schneekloth T, Kolla BP, Oesterle T, Loukianova LL, Skime MK, Ho AMC, Ngo Q, Skillon C, Ho MF, Weinshilboum R, Biernacka JM. Corrigendum to "genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder" [Drug Alcohol Depend. 243 (2023) 109753]. Drug and Alcohol Dependence. 2023 Sep; 250:110888
   
8. Karpyak VM, Coombes BJ, Geske JR, Pazdernik VM, Schneekloth T, Kolla BP, Oesterle T, Loukianova LL, Skime MK, Ho AM, Ngo Q, Skillon C, Ho MF, Weinshilboum R, Biernacka JM. Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder. Drug Alcohol Depend. 2023 Feb 1; 243:109753 Epub 2022 Dec 24
   View PubMed
9. Zhang L, Sarangi V, Liu D, Ho MF, Grassi AR, Wei L, Moon I, Vierkant RA, Larson NB, Lazaridis KN, Athreya AP, Wang L, Weinshilboum R. ACE2 and TMPRSS2 SARS-CoV-2 infectivity genes: deep mutational scanning and characterization of missense variants. Hum Mol Genet. 2022 Dec 16; 31 (24):4183-4192
   View PubMed
10. Ho MF, Zhang C, Moon I, Wei L, Coombes B, Biernacka J, Skime M, Choi DS, Frye M, Schmidt K, Gliske K, Braughton J, Ngo Q, Skillon C, Seppala M, Oesterle T, Karpyak V, Li H, Weinshilboum R. Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism. Mol Metab. 2022 Sep; 63:101534 Epub 2022 June 22
    View PubMed
11. Ho MF, Zhang C, Wei L, Zhang L, Moon I, Geske JR, Skime MK, Choi DS, Biernacka JM, Oesterle TS, Frye MA, Seppala MD, Karpyak VM, Li H, Weinshilboum RM. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. Br J Pharmacol. 2022 Jul; 179 (13):3330-3345 Epub 2022 Feb 08
    View PubMed
12. Ho MF, Zhang C, Moon I, Coombes BJ, Biernacka J, Skime M, Choi DS, Croarkin PE, Frye MA, Ngo Q, Skillon C, Oesterle TS, Karpyak VM, Li H, Weinshilboum RM. Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder. Front Pharmacol. 2022; 13:986238 Epub 2022 Sept 01
    View PubMed
13. Biernacka JM, Coombes BJ, Batzler A, Ho AM, Geske JR, Frank J, Hodgkinson C, Skime M, Colby C, Zillich L, Pozsonyiova S, Ho MF, Kiefer F, Rietschel M, Weinshilboum R, O'Malley SS, Mann K, Anton R, Goldman D, Karpyak VM. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 Nov; 46(12):2132-2139. Epub 2021 Jul 23.
    View PubMed
14. Ho MF, Zhang C, Zhang L, Wei L, Zhou Y, Moon I, Geske JR, Choi DS, Biernacka J, Frye M, Wen Z, Karpyak VM, Li H, Weinshilboum R. TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. Mol Psychiatry. 2021 Jul; 26 (7):3122-3133 Epub 2020 Aug 04
    View PubMed
15. Zhang L, Sarangi V, Ho MF, Moon I, Kalari KR, Wang L, Weinshilboum RM. SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function. Drug Metab Dispos. 2021 May; 49 (5):395-404 Epub 2021 Mar 03
    View PubMed
16. Nguyen TTL, Liu D, Ho MF, Athreya AP, Weinshilboum R. Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction. Front Pharmacol. 2020; 11:614048 Epub 2021 Jan 11
    View PubMed
17. Ho MF, Weinshilboum RM. Catechol O-Methyltransferase Pharmacogenomics: Challenges and Opportunities. Clin Pharmacol Ther. 2019 Aug; 106 (2):281-283 Epub 2019 May 13
    View PubMed
18. Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM. Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19. Drug Metab Dispos. 2019 Apr; 47 (4):425-435 Epub 2019 Feb 11
    View PubMed
19. Ho MF, Zhang C, Zhang L, Li H, Weinshilboum RM. Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine. Front Pharmacol. 2019; 10:1302 Epub 2019 Nov 05
    View PubMed
20. Ho MF, Lummertz da Rocha E, Zhang C, Ingle JN, Goss PE, Shepherd LE, Kubo M, Wang L, Li H, Weinshilboum RM. TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor kappaB p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther. 2018 Jun; 365 (3):700-710 Epub 2018 Mar 28
    View PubMed
21. Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochem Pharmacol. 2018 Jun; 152:279-292. Epub 2018 Apr 03.
    View PubMed
22. Ho MF, Ingle JN, Bongartz T, Kalari KR, Goss PE, Shepherd LE, Mushiroda T, Kubo M, Wang L, Weinshilboum RM. TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-kappaB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response. Mol Pharmacol. 2017 Aug; 92 (2):175-184 Epub 2017 June 14
    View PubMed
23. Ho MF, Weinshilboum RM. Immune Mediator Pharmacogenomics: TCL1A SNPs and Estrogen-Dependent Regulation of Inflammation. J Nat Sci. 2017 Aug; 3 (8)
    View PubMed
24. Liu D, Ho MF, Schaid DJ, Scherer SE, Kalari K, Liu M, Biernacka J, Yee V, Evans J, Carlson E, Carlson E, Goetz MP, Kubo M, Wickerham DL, Wang L, Ingle JN, Weinshilboum RM. Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. NPJ Breast Cancer. 2017; 3:30 Epub 2017 Aug 21
    View PubMed
25. Ho MF, Bongartz T, Liu M, Kalari KR, Goss PE, Shepherd LE, Goetz MP, Kubo M, Ingle JN, Wang L, Weinshilboum RM. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. Mol Endocrinol. 2016 Mar; 30 (3):382-98 Epub 2016 Feb 11
    View PubMed
26. Ho MF, Low LM, Rose'Meyer RB. Pharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension. PLoS One. 2016; 11 (2):e0150021 Epub 2016 Feb 23
    View PubMed
27. Ho M. Vascular adenosine receptors: potential clinical applications Current Vascular Pharmacology.2013May:(11(3)):307-37.
    View PubMed